Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Avacopan on Simvastatin PK in Healthy Volunteers
NCT06207682Phase 1Completed
- Sponsor
- Amgen
- Start
- Jun 2022
- Primary completion
- Aug 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of avacopan in Antineutrophil cytoplasmic antibody-associated vasculitis (AAV) (2 arms), sponsored by Amgen. Primary endpoints: Maximum Observed Plasma Concentration (Cmax) of Simvastatin, Cmax of beta-hydroxy-simvastatin Acid and 4 more. Started Jun 2022; status: completed.
02
Drugs
avacopan
03
Conditions
Antineutrophil cytoplasmic antibody-associated vasculitis (AAV)
Beyond the preview
Go deeper on NCT06207682.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06207682.